Biocept, Inc. (NASDAQ: BIOC) Stock Competitors & Peer Comparison
See BIOC's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BIOC and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIOC | $0.43 | +0.00% | 450.8K | -0.01 | -$48.17 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.66% |
| TMO | $694.76 | +2.63% | 257.5B | 30.00 | $23.16 | +0.27% |
| DHR | $230.25 | +1.73% | 161.9B | 28.86 | $7.98 | +0.66% |
| IDXX | $676.04 | +0.79% | 53.3B | 47.54 | $14.22 | N/A |
| A | $174.76 | +1.73% | 49.3B | 30.08 | $5.81 | +0.59% |
| WAT | $457.60 | +1.00% | 44.9B | 33.45 | $13.68 | N/A |
| IQV | $271.83 | +2.62% | 44.8B | 22.40 | $12.13 | N/A |
| NTRA | $310.67 | -14.59% | 44.7B | -235.14 | -$1.32 | N/A |
| MTD | $1,722.15 | +2.57% | 34.5B | 39.56 | $43.51 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
BIOC vs DHR-PB Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, BIOC's ROE is -1.38%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, BIOC is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
BIOC vs TMO Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, TMO has a market cap of 257.5B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while TMO trades at $694.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas TMO's P/E ratio is 30.00. In terms of profitability, BIOC's ROE is -1.38%, compared to TMO's ROE of +0.13%. Regarding short-term risk, BIOC is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
BIOC vs DHR Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, DHR has a market cap of 161.9B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while DHR trades at $230.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas DHR's P/E ratio is 28.86. In terms of profitability, BIOC's ROE is -1.38%, compared to DHR's ROE of +0.08%. Regarding short-term risk, BIOC is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check DHR's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
BIOC vs IDXX Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, IDXX has a market cap of 53.3B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while IDXX trades at $676.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas IDXX's P/E ratio is 47.54. In terms of profitability, BIOC's ROE is -1.38%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, BIOC is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check IDXX's competition here
Agilent Technologies, Inc. (NYSE: A)
BIOC vs A Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, A has a market cap of 49.3B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while A trades at $174.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas A's P/E ratio is 30.08. In terms of profitability, BIOC's ROE is -1.38%, compared to A's ROE of +0.20%. Regarding short-term risk, BIOC is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check A's competition here
Waters Corporation (NYSE: WAT)
BIOC vs WAT Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, WAT has a market cap of 44.9B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while WAT trades at $457.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas WAT's P/E ratio is 33.45. In terms of profitability, BIOC's ROE is -1.38%, compared to WAT's ROE of +0.01%. Regarding short-term risk, BIOC is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check WAT's competition here
IQVIA Holdings Inc. (NYSE: IQV)
BIOC vs IQV Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, IQV has a market cap of 44.8B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while IQV trades at $271.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas IQV's P/E ratio is 22.40. In terms of profitability, BIOC's ROE is -1.38%, compared to IQV's ROE of +0.22%. Regarding short-term risk, BIOC is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check IQV's competition here
Natera, Inc. (NASDAQ: NTRA)
BIOC vs NTRA Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, NTRA has a market cap of 44.7B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while NTRA trades at $310.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas NTRA's P/E ratio is -235.14. In terms of profitability, BIOC's ROE is -1.38%, compared to NTRA's ROE of -0.09%. Regarding short-term risk, BIOC is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check NTRA's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
BIOC vs MTD Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, MTD has a market cap of 34.5B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while MTD trades at $1,722.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas MTD's P/E ratio is 39.56. In terms of profitability, BIOC's ROE is -1.38%, compared to MTD's ROE of +149.66%. Regarding short-term risk, BIOC is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check MTD's competition here
Illumina, Inc. (NASDAQ: ILMN)
BIOC vs ILMN Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, ILMN has a market cap of 32.2B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while ILMN trades at $213.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas ILMN's P/E ratio is 42.36. In terms of profitability, BIOC's ROE is -1.38%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, BIOC is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check ILMN's competition here
Labcorp Holdings Inc. (NYSE: LH)
BIOC vs LH Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, LH has a market cap of 29.8B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while LH trades at $366.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas LH's P/E ratio is 21.76. In terms of profitability, BIOC's ROE is -1.38%, compared to LH's ROE of +0.12%. Regarding short-term risk, BIOC is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check LH's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
BIOC vs DGX Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, DGX has a market cap of 28.2B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while DGX trades at $255.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas DGX's P/E ratio is 25.22. In terms of profitability, BIOC's ROE is -1.38%, compared to DGX's ROE of +0.15%. Regarding short-term risk, BIOC is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check DGX's competition here
Guardant Health, Inc. (NASDAQ: GH)
BIOC vs GH Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, GH has a market cap of 20.3B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while GH trades at $150.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas GH's P/E ratio is -43.33. In terms of profitability, BIOC's ROE is -1.38%, compared to GH's ROE of +2.49%. Regarding short-term risk, BIOC is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
BIOC vs EXAS Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas EXAS's P/E ratio is -95.37. In terms of profitability, BIOC's ROE is -1.38%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, BIOC is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
BIOC vs MEDP Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, MEDP has a market cap of 18.3B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while MEDP trades at $653.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas MEDP's P/E ratio is 36.22. In terms of profitability, BIOC's ROE is -1.38%, compared to MEDP's ROE of +1.00%. Regarding short-term risk, BIOC is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check MEDP's competition here
Revvity, Inc. (NYSE: RVTY)
BIOC vs RVTY Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, RVTY has a market cap of 17.3B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while RVTY trades at $155.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas RVTY's P/E ratio is 29.01. In terms of profitability, BIOC's ROE is -1.38%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, BIOC is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
BIOC vs ILMNV Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas ILMNV's P/E ratio is N/A. In terms of profitability, BIOC's ROE is -1.38%, compared to ILMNV's ROE of N/A. Regarding short-term risk, BIOC is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check ILMNV's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
BIOC vs CRL Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, CRL has a market cap of 16.2B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while CRL trades at $337.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas CRL's P/E ratio is 34.09. In terms of profitability, BIOC's ROE is -1.38%, compared to CRL's ROE of +0.01%. Regarding short-term risk, BIOC is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
BIOC vs ICLR Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, ICLR has a market cap of 15.3B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while ICLR trades at $204.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas ICLR's P/E ratio is 16.71. In terms of profitability, BIOC's ROE is -1.38%, compared to ICLR's ROE of +0.05%. Regarding short-term risk, BIOC is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check ICLR's competition here
PerkinElmer, Inc. (NYSE: PKI)
BIOC vs PKI Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas PKI's P/E ratio is 41.45. In terms of profitability, BIOC's ROE is -1.38%, compared to PKI's ROE of +0.04%. Regarding short-term risk, BIOC is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check PKI's competition here
Qiagen N.V. (NYSE: QGEN)
BIOC vs QGEN Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, QGEN has a market cap of 10.4B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while QGEN trades at $50.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas QGEN's P/E ratio is 20.79. In terms of profitability, BIOC's ROE is -1.38%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, BIOC is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
BIOC vs RDNT Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, RDNT has a market cap of 6B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while RDNT trades at $76.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas RDNT's P/E ratio is 164.87. In terms of profitability, BIOC's ROE is -1.38%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, BIOC is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check RDNT's competition here
GRAIL Inc. (NASDAQ: GRAL)
BIOC vs GRAL Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, GRAL has a market cap of 5.4B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while GRAL trades at $121.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas GRAL's P/E ratio is -12.45. In terms of profitability, BIOC's ROE is -1.38%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, BIOC is more volatile compared to GRAL. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check GRAL's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
BIOC vs BLLN Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, BLLN has a market cap of 5.4B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while BLLN trades at $113.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas BLLN's P/E ratio is 162.81. In terms of profitability, BIOC's ROE is -1.38%, compared to BLLN's ROE of +0.09%. Regarding short-term risk, BIOC is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
BIOC vs SHC Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, SHC has a market cap of 4.6B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while SHC trades at $16.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas SHC's P/E ratio is 16.68. In terms of profitability, BIOC's ROE is -1.38%, compared to SHC's ROE of +0.26%. Regarding short-term risk, BIOC is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
BIOC vs SYNH Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas SYNH's P/E ratio is 61.40. In terms of profitability, BIOC's ROE is -1.38%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, BIOC is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check SYNH's competition here
CareDx, Inc (NASDAQ: CDNA)
BIOC vs CDNA Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, CDNA has a market cap of 4.1B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while CDNA trades at $78.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas CDNA's P/E ratio is 93.46. In terms of profitability, BIOC's ROE is -1.38%, compared to CDNA's ROE of +0.34%. Regarding short-term risk, BIOC is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
BIOC vs OLK Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas OLK's P/E ratio is -96.59. In terms of profitability, BIOC's ROE is -1.38%, compared to OLK's ROE of -0.07%. Regarding short-term risk, BIOC is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check OLK's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
BIOC vs NEO Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, NEO has a market cap of 2.2B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while NEO trades at $16.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas NEO's P/E ratio is 129.54. In terms of profitability, BIOC's ROE is -1.38%, compared to NEO's ROE of -0.04%. Regarding short-term risk, BIOC is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check NEO's competition here
Veracyte, Inc. (NASDAQ: VCYT)
BIOC vs VCYT Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, VCYT has a market cap of 1.9B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while VCYT trades at $24.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas VCYT's P/E ratio is 12.07. In terms of profitability, BIOC's ROE is -1.38%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, BIOC is more volatile compared to VCYT. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check VCYT's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
BIOC vs WGS Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, WGS has a market cap of 1.9B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while WGS trades at $62.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas WGS's P/E ratio is 173.25. In terms of profitability, BIOC's ROE is -1.38%, compared to WGS's ROE of -0.39%. Regarding short-term risk, BIOC is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
BIOC vs PSNL Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while PSNL trades at $15.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas PSNL's P/E ratio is -14.48. In terms of profitability, BIOC's ROE is -1.38%, compared to PSNL's ROE of -0.50%. Regarding short-term risk, BIOC is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
BIOC vs OPK Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, OPK has a market cap of 1.3B. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while OPK trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas OPK's P/E ratio is -19.17. In terms of profitability, BIOC's ROE is -1.38%, compared to OPK's ROE of -0.12%. Regarding short-term risk, BIOC is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
BIOC vs CSTL Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, CSTL has a market cap of 993.2M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while CSTL trades at $32.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas CSTL's P/E ratio is -49.26. In terms of profitability, BIOC's ROE is -1.38%, compared to CSTL's ROE of -0.05%. Regarding short-term risk, BIOC is more volatile compared to CSTL. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
BIOC vs FLGT Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, FLGT has a market cap of 654.3M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while FLGT trades at $23.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas FLGT's P/E ratio is 2378.00. In terms of profitability, BIOC's ROE is -1.38%, compared to FLGT's ROE of -0.09%. Regarding short-term risk, BIOC is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
BIOC vs GRALV Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas GRALV's P/E ratio is N/A. In terms of profitability, BIOC's ROE is -1.38%, compared to GRALV's ROE of N/A. Regarding short-term risk, BIOC is more volatile compared to GRALV. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check GRALV's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
BIOC vs MYGN Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, MYGN has a market cap of 564.3M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while MYGN trades at $5.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas MYGN's P/E ratio is -45.38. In terms of profitability, BIOC's ROE is -1.38%, compared to MYGN's ROE of -0.40%. Regarding short-term risk, BIOC is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
BIOC vs CO Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas CO's P/E ratio is 5.06. In terms of profitability, BIOC's ROE is -1.38%, compared to CO's ROE of +0.11%. Regarding short-term risk, BIOC is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
BIOC vs FLDM Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas FLDM's P/E ratio is -4.74. In terms of profitability, BIOC's ROE is -1.38%, compared to FLDM's ROE of +0.26%. Regarding short-term risk, BIOC is more volatile compared to FLDM. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check FLDM's competition here
Exagen Inc. (NASDAQ: XGN)
BIOC vs XGN Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, XGN has a market cap of 140.5M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while XGN trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas XGN's P/E ratio is -7.16. In terms of profitability, BIOC's ROE is -1.38%, compared to XGN's ROE of -1.22%. Regarding short-term risk, BIOC is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check XGN's competition here
Genetron Holdings Limited (NASDAQ: GTH)
BIOC vs GTH Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas GTH's P/E ratio is -1.11. In terms of profitability, BIOC's ROE is -1.38%, compared to GTH's ROE of -1.01%. Regarding short-term risk, BIOC is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
BIOC vs GENE Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas GENE's P/E ratio is -38.25. In terms of profitability, BIOC's ROE is -1.38%, compared to GENE's ROE of -1.85%. Regarding short-term risk, BIOC is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check GENE's competition here
Freenome, Inc. (NASDAQ: FRNM)
BIOC vs FRNM Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, FRNM has a market cap of 83M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while FRNM trades at $10.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas FRNM's P/E ratio is N/A. In terms of profitability, BIOC's ROE is -1.38%, compared to FRNM's ROE of N/A. Regarding short-term risk, BIOC is more volatile compared to FRNM. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check FRNM's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
BIOC vs IMDX Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, IMDX has a market cap of 81.5M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while IMDX trades at $2.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas IMDX's P/E ratio is -1.67. In terms of profitability, BIOC's ROE is -1.38%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, BIOC is more volatile compared to IMDX. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check IMDX's competition here
Biodesix, Inc. (NASDAQ: BDSX)
BIOC vs BDSX Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, BDSX has a market cap of 69.8M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while BDSX trades at $8.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas BDSX's P/E ratio is -2.71. In terms of profitability, BIOC's ROE is -1.38%, compared to BDSX's ROE of -4.42%. Regarding short-term risk, BIOC is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check BDSX's competition here
Precipio, Inc. (NASDAQ: PRPO)
BIOC vs PRPO Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, PRPO has a market cap of 33.5M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while PRPO trades at $18.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas PRPO's P/E ratio is -28.78. In terms of profitability, BIOC's ROE is -1.38%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, BIOC is more volatile compared to PRPO. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
BIOC vs AKU Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas AKU's P/E ratio is -0.13. In terms of profitability, BIOC's ROE is -1.38%, compared to AKU's ROE of -5.32%. Regarding short-term risk, BIOC is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check AKU's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
BIOC vs BIAF Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, BIAF has a market cap of 17.3M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while BIAF trades at $2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas BIAF's P/E ratio is -0.32. In terms of profitability, BIOC's ROE is -1.38%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, BIOC is more volatile compared to BIAF. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check BIAF's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
BIOC vs CEMI Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas CEMI's P/E ratio is -0.63. In terms of profitability, BIOC's ROE is -1.38%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, BIOC is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
BIOC vs ENZ Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas ENZ's P/E ratio is -2.24. In terms of profitability, BIOC's ROE is -1.38%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, BIOC is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check ENZ's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
BIOC vs QUCY Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, QUCY has a market cap of 16.3M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while QUCY trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas QUCY's P/E ratio is -0.03. In terms of profitability, BIOC's ROE is -1.38%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, BIOC is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check QUCY's competition here
Psychemedics Corporation (NASDAQ: PMD)
BIOC vs PMD Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas PMD's P/E ratio is -5.24. In terms of profitability, BIOC's ROE is -1.38%, compared to PMD's ROE of -0.32%. Regarding short-term risk, BIOC is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
BIOC vs ME Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas ME's P/E ratio is -0.03. In terms of profitability, BIOC's ROE is -1.38%, compared to ME's ROE of -3.47%. Regarding short-term risk, BIOC is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check ME's competition here
MDxHealth S.A. (NASDAQ: MDXH)
BIOC vs MDXH Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, MDXH has a market cap of 15.3M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while MDXH trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas MDXH's P/E ratio is -0.22. In terms of profitability, BIOC's ROE is -1.38%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, BIOC is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check MDXH's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
BIOC vs MYNZ Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, BIOC's ROE is -1.38%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, BIOC is more volatile compared to MYNZ. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
BIOC vs BNR Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, BNR has a market cap of 14.5M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while BNR trades at $13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas BNR's P/E ratio is -15.79. In terms of profitability, BIOC's ROE is -1.38%, compared to BNR's ROE of -0.13%. Regarding short-term risk, BIOC is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check BNR's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
BIOC vs CHEK Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas CHEK's P/E ratio is -0.43. In terms of profitability, BIOC's ROE is -1.38%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, BIOC is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
BIOC vs CNTG Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas CNTG's P/E ratio is -0.23. In terms of profitability, BIOC's ROE is -1.38%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, BIOC is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check CNTG's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
BIOC vs APDN Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas APDN's P/E ratio is -0.10. In terms of profitability, BIOC's ROE is -1.38%, compared to APDN's ROE of -7.23%. Regarding short-term risk, BIOC is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
BIOC vs NDRA Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, NDRA has a market cap of 7.1M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while NDRA trades at $4.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas NDRA's P/E ratio is -0.70. In terms of profitability, BIOC's ROE is -1.38%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, BIOC is more volatile compared to NDRA. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check NDRA's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
BIOC vs BIAFW Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, BIAFW has a market cap of 7M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while BIAFW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas BIAFW's P/E ratio is 0.75. In terms of profitability, BIOC's ROE is -1.38%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, BIOC is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check BIAFW's competition here
Invitae Corporation (NYSE: NVTA)
BIOC vs NVTA Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas NVTA's P/E ratio is -0.00. In terms of profitability, BIOC's ROE is -1.38%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, BIOC is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
BIOC vs LMDXW Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, BIOC's ROE is -1.38%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, BIOC is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
BIOC vs LMDX Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas LMDX's P/E ratio is -0.01. In terms of profitability, BIOC's ROE is -1.38%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, BIOC is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check LMDX's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
BIOC vs ADVB Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, ADVB has a market cap of 3.3M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while ADVB trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas ADVB's P/E ratio is -18.32. In terms of profitability, BIOC's ROE is -1.38%, compared to ADVB's ROE of +1.22%. Regarding short-term risk, BIOC is more volatile compared to ADVB. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check ADVB's competition here
DermTech, Inc. (NASDAQ: DMTK)
BIOC vs DMTK Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas DMTK's P/E ratio is -0.04. In terms of profitability, BIOC's ROE is -1.38%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, BIOC is more volatile compared to DMTK. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
BIOC vs NOTV Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas NOTV's P/E ratio is -0.03. In terms of profitability, BIOC's ROE is -1.38%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, BIOC is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
BIOC vs SQL Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas SQL's P/E ratio is -0.40. In terms of profitability, BIOC's ROE is -1.38%, compared to SQL's ROE of -30.46%. Regarding short-term risk, BIOC is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
BIOC vs AWH Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas AWH's P/E ratio is -0.09. In terms of profitability, BIOC's ROE is -1.38%, compared to AWH's ROE of +1.62%. Regarding short-term risk, BIOC is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check AWH's competition here
iSpecimen Inc. (NASDAQ: ISPC)
BIOC vs ISPC Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, ISPC has a market cap of 2M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while ISPC trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas ISPC's P/E ratio is -0.03. In terms of profitability, BIOC's ROE is -1.38%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, BIOC is more volatile compared to ISPC. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check ISPC's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
BIOC vs HTGM Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas HTGM's P/E ratio is -0.03. In terms of profitability, BIOC's ROE is -1.38%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, BIOC is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check HTGM's competition here
SeqLL Inc. (NASDAQ: SQLLW)
BIOC vs SQLLW Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, BIOC's ROE is -1.38%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, BIOC is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
BIOC vs WGSWW Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, BIOC's ROE is -1.38%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, BIOC is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check WGSWW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
BIOC vs OCDX Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, OCDX has a market cap of 0. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas OCDX's P/E ratio is -42.28. In terms of profitability, BIOC's ROE is -1.38%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, BIOC is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check OCDX's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
BIOC vs PRXL Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, PRXL has a market cap of 0. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas PRXL's P/E ratio is 42.97. In terms of profitability, BIOC's ROE is -1.38%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, BIOC is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check PRXL's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
BIOC vs NDRAW Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas NDRAW's P/E ratio is N/A. In terms of profitability, BIOC's ROE is -1.38%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, BIOC is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check NDRAW's competition here
Danaher Corporation (NYSE: DHR-PA)
BIOC vs DHR-PA Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, BIOC's ROE is -1.38%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, BIOC is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for BIOC.Check DHR-PA's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
BIOC vs CHEKZ Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, BIOC's ROE is -1.38%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, BIOC is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check CHEKZ's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
BIOC vs MEUSW Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas MEUSW's P/E ratio is N/A. In terms of profitability, BIOC's ROE is -1.38%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, BIOC is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check MEUSW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
BIOC vs BNGOW Comparison November 2026
Biocept, Inc. (NASDAQ: BIOC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOC stands at 450.8K. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, BIOC is priced at $0.43 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOC currently has a P/E ratio of -0.01, whereas BNGOW's P/E ratio is N/A. In terms of profitability, BIOC's ROE is -1.38%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, BIOC is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for BIOC.Check BNGOW's competition here